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Objective: We previously demonstrated the ability of matrilin-3 to modulate the gene expression proﬁle
of primary human chondrocytes (PHCs) toward a state favoring cartilage catabolism. The structure within
matrilin-3 responsible for the induction of these catabolic genes is unknown. Here, we investigated the
potential of matrilin-3 (MATN3) and truncated matrilin-3 proteins, in both monomeric and oligomeric
form, to stimulate interleukin (IL)-6 release in PHCs.
Methods: We expressed full-length matrilin-3 oligomers, matrilin-3 von Willebrand factor A (VWA)
domain oligomers, matrilin-3 four epidermal growth factor (EGF) domain oligomers, matrilin-3 mono-
mers without oligomerization domains, matrilin-3 VWA domain monomers, and matrilin-3 4EGF
monomers. We then incubated PHCs in the absence or presence of full-length matrilin-3 or one of the
truncated matrilin-3 proteins and ﬁnally determined the release of IL-6 in cell-culture supernatants.
Results: The addition of full-length matrilin-3 oligomers, matrilin-3 VWA domain oligomers, and, less
pronounced, matrilin-3 monomers without oligomerization domains, and matrilin-3 4EGF-oligomers to
the cell-culture medium led to a signiﬁcant induction of IL-6 in PHCs.
Discussion: Based on recombinant expression of different matrilin-3 domains in both monomeric and
oligomeric form, this work demonstrated that the VWA1 domain of matrilin-3 is primarily responsible
for the induction of IL-6 release and that the oligomerization of the VWA1 domain markedly promotes its
activity.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
We previously demonstrated the ability of matrilin-3 to
modulate the gene expression proﬁle of primary human chon-
drocytes (PHCs) toward a state favoring cartilage catabolism.
Moreover, stimulation of PHCs with matrilin-3 resulted in a sig-
niﬁcant induction of the proinﬂammatory cytokines interleukin
(IL)-6, IL-8, IL-1 and tumor-necrosis factor (TNF)a, the matrix
metalloproteinase (MMP)1, 3, and 13, the inducible nitric oxide
synthase (iNOS) and cyclooxygenase-2 (COX-2)1. However, the
structure within matrilin-3 responsible for the induction of these
catabolic genes is unknown.A.R. Klatt, Institut für Klini-
62, 50924 Köln, Germany.
latt).
s Research Society International. PThematrilins form a four-member family of modular, oligomeric
extracellular matrix proteins that are most strongly expressed in
cartilage, but are also present in many other forms of extracellular
matrix2. Matrilins show a distinct structural heterogeneity caused
byalternative splicing, the formation of homo- and heterooligomers
and proteolytic processing, which all affect their interactions. They
are thought to serve as adaptor proteins mediating interactions
between themajor cartilage collagen ﬁbrils, collagen VI microﬁbrils
and the aggrecan gel2. Except for matrilin-3, mature matrilins
consist of subunits with two von Willebrand factor A (VWA)-like
domains that are connected by a variable number of epidermal
growth factor (EGF)-like domains, and these subunits form trimers
or tetramers via a C-terminal a-helical coiled-coil domain. Matrilin-
3 is the smallest familymember and ismainly expressed in cartilage.
Its subunits consist of a single VWA-like domain, followed by four
EGF-like domains and a C-terminal coiled-coil domain3. A common
feature of VWA domains is their involvement in the formation of
intra- or extracellularmultiprotein complexes (for review see4). EGFublished by Elsevier Ltd. All rights reserved.
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in manymembrane-bound or secreted proteins. Both VWA and EGF
domains could potentially modulate the gene expression proﬁle of
PHCs after binding to cell-surface receptors.
In the present study, we aimed at determining which domain
within matrilin-3 has the ability to induce catabolic genes in PHCs.
To accomplish this, we recombinantly expressed different matrilin-
3 domains in both monomeric and oligomeric form (Fig. 1) and
investigated their potential to stimulate IL-6 release in PHCs.
Material and methods
Expression and puriﬁcation of recombinant matrilin-3 and
recombinant matrilin-3 domains
cDNA constructs coding for murine full-length matrilin-3 and
different matrilin-3 domains were generated by Reverse
transcription polymerase chain reaction (RT-PCR) and cloned
with 50-terminal SpeI and 30-terminal BamHI restriction sites using
oligonucleotide primers (Supplementary Material). The ampliﬁed
PCR products were inserted into a modiﬁed pCEP-Pu vector con-
taining an N-terminal BM-40 signal peptide5 and a C-terminal
One-STrEP-tag (IBA GmbH) downstream of the restriction sites.
Each of the expression constructs was transfected into 293EBNA
cells with Lipofectamine 2000 (Invitrogen), according to the
manufacturer’s instructions. The cell lines were selected with pu-
romycin (1 mg/ml) and cultured under serum-free conditions prior
to harvesting conditioned cell-culture supernatants. Cells
expressing full-lengthmatrilin-3, as well as the VWA1 domainwith
coiled-coil domains (A1cc) and the 4EGF domains with coiled-coil
domains (4EGFcc) were cultured with 10% SeraPlus (PAN) to
reduce proteolytic processing, thereby increasing the yield of intact
matrilin-3 oligomers. One-STrEP-tagged matrilin-3 and matrilin-3
domains were afﬁnity puriﬁed from conditioned supernatants
using a Strep-Tactin Superﬂow column (IBA).
Isolation, cultures and stimulation of PHCs
Articular cartilage taken from femoral condyles and tibial pla-
teaus of human knee joints was obtained from patients sufferingFig. 1. Matrilin-3 domain structure, designation and predicted molecular weights of
the recombinant proteins. Full-length (ﬂc) matrilin-3 and the oligomeric 4EGFcc
domain occur in different oligomeric forms due to proteolytic cleavage during
recombinant expression. For these two proteins, we assigned a mean molecular weight
according to the intensity of the subforms in SDSePAGE (Fig. 2). * denotes proteins
with a coiled-coil domain that can form higher oligomers.from osteoarthritis at the time of total joint replacement surgery.
Patient age at the time of surgery ranged from 52 to 78 years.
Chondrocytes were taken from whole condyles. To isolate PHCs,
cartilage samples were rinsed with Dulbecco’s Modiﬁed Eagle
Medium (DMEM)/F12 medium (Gibco), minced, and digested with
Pronase (0.4%, 90 min, Calbiochem) and Collagenase-P (0.025%,
16 h, Roche) in DMEM/F12 medium containing 5% BD-NU serum
(BD Biosciences). PHCs were ﬁltered with a 100 mm and a 40 mm
ﬁlter, seeded (1  106 cells/well) in six-well multiwell plates (Fal-
con) in DMEM/F12 (PAN) containing 10% BD-NU serum (BD Bio-
sciences) and 50 mg/ml gentamicin/ml (Gibco) and then cultivated
in a CO2 incubator (5% CO2, 37 C).
Cells were incubated in the absence or presence of full-length
matrilin-3 or matrilin-3 domains at different concentrations. For
this purpose, matrilin-3 and matrilin-3 domains were dialyzed
against culture medium. The dialysis buffer (devoid of full-length
matrilin-3 and matrilin-3 domains) was used as a negative con-
trol. The concentrations were determined by using the Bio-Rad
Protein Assay (BIO-RAD). The viability of the cells was veriﬁed by
the 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) (Thiazolyl Blue Tetrazolium Bromide) test (Sigma), according
to the manufacturer’s instructions. IL-6 release was related to the
values of the negative controls and depicted as fold induction. To
further demonstrate the speciﬁcity of stimulation, prior to stimu-
lation culture medium was depleted for matrilin-3, matrilin-3
monomer without oligomerization domains (dCT), and A1cc,
respectively, by incubation with Strep-Tactin Superﬂow resin (IBA)
for 1 h and subsequent centrifugation (at 84 g).
Sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDSePAGE) and immunoblotting
Cell-culture supernatants were separated on a 4e12% Bis-Tris gel
(Invitrogen) and stained by Coomassie Brilliant Blue (Merck). For
immunoblotting, the proteins were transferred to a Polyvinylidene
ﬂuoride (PVDF) membrane (0.45 mm) (Invitrogen). Membranes were
blockedwith 5%milk powder, incubated in an appropriate dilution of
an afﬁnity-puriﬁed polyclonal rabbit anti-matrilin-3 antiserum3, and
ﬁnally incubated in a 1/5,000 dilution of horseradish peroxidase-
conjugated polyclonal donkey anti-rabbit IgG antiserum (Amer-
sham Pharmacia Biotech). Membranes were treated with ECL Plus
according to the manufacturer’s instructions (Amersham Pharmacia
Biotech), and visualized on Hyperﬁlm (Amersham Bioscience).
Enzyme-linked immuno sorbent assay (ELISA)
Release of IL-6 was determined in cell-culture supernatants
using a commercial IL-6 ELISA kit (BD Bioscience) in accordance
with the manufacturer’s protocol.
Statistical analysis
The term dose dependency as used in this text refers to the
magnitude of a biological effect as a function of the concentration of
the inducing agent. The biological effect changes when the con-
centration of the inducing agent changes, both are correlated.
Therefore tests of correlation can be performed to estimate dose
dependency. Here, Pearson’s correlation coefﬁcient analysis was
used. To test for differences between effects, irrespective of
potentially underlying effects of dose dependency, Analysis of
variance between groups (ANOVA) was used. To test for normality,
the ShapiroeWilk test was used (not shown). All measurements
were normally distributed, a prerequisite for applying ANOVA or
Pearson’s correlation coefﬁcient analysis. P-values less than 0.05
indicate signiﬁcant results, while P-values less than 0.01 indicate
Fig. 2. Afﬁnity-puriﬁed recombinant matrilin-3 proteins were subjected to SDSePAGE
on 4e12% gels (1e5 mg loaded) under non-reducing and reducing conditions and
visualized by Coomassie staining. Proteins with a coiled-coil domain form oligomers
that are stabilized by interchain disulﬁde bridges at the N-terminus of the coiled-coil
domain. Consistent with their behavior on SDSePAGE, these oligomeric proteins
release monomers if reduced.
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n ¼ number of patients; F ¼ test statistic (ANOVA); and
r ¼ correlation coefﬁcient (Pearson).
Results
Cloning, expression and puriﬁcation of full-length matrilin-3 and
truncated matrilin-3 proteins
In our previous work, we demonstrated the ability of matrilin-3
to modulate the gene expression proﬁle of PHCs. To investigate
which domain of matrilin-3 is able to stimulate gene induction, we
recombinantly expressed and puriﬁed full-length matrilin-3 tet-
ramers (ﬂc), the single A1 domain (A1), four EGF domains (4EGF),
and matrilin-3 without the C-terminal oligomerization domainFig. 3. Dose-dependent induction of IL-6 by matrilin-3 proteins. PHCs from at least six (12
domains in different equimolar concentrations (50, 100, 200 nM). Cell-culture supernatants w
release, i.e., release relative to basal release in control cultures. The oligomeric full-length m
IL-6 in a dose-dependent manner. Error bars represent the 95% conﬁdence interval. */** indic
values or correlations, respectively). Asterisks in parentheses refer to the statistical signiﬁc(dCT) (Fig. 1). Furthermore, we expressed a matrilin-3 VWA domain
oligomer (A1cc), as well as an oligomer containing only the four
EGF domains (4EGFcc), by use of the C-terminal coiled-coil oligo-
merization domain of matrilin-3 (Fig. 1). The identity and the purity
of all proteins were veriﬁed by SDSePAGE followed by immunoblot
and Coomassie staining (Fig. 2), respectively.
Matrilin-3 contains 28 cysteine residues, 26 of which form
intrachain disulﬁde bonds. Two form disulﬁde bonds connecting
the N- and C-terminus of the VWA domain and 24 are involved in
the characteristic disulﬁde bond pattern of the four EGF domains.
Two closely spaced cysteine residues present at the N-terminus of
all matrilin coiled-coil domains form a ring of interchain disulﬁde
bonds that stabilizes the coiled-coil domain. This was revealed by
Nuclear magnetic resonance (NMR) analysis of the structure of the
matrilin-1 coiled-coil domain6. In the present work, the ﬂc as well
as the A1cc and 4EGFcc domains formed higher oligomers, which
released monomers after reduction, and showed the expected
migration pattern on SDSePAGE (Fig. 2). The 4EGF protein gave a
band corresponding to 40e50 kDa, which indicates dimer forma-
tion. We therefore veriﬁed the correct folding of the 4EGF protein
by circular dichroism spectroscopy (data not shown).
Different ranges of yield of recombinant protein were obtained
for the different protein preparations: ﬂc e 30e340 mg/ml; dCT e
427e1904 mg/ml; A1e295e469 mg/ml; 4Ee 162e467 mg/ml; A1cc:
135e287 mg/ml; 4Ecc428 e 159 mg/ml. Protein preparations were
adjusted for molar concentration differences by dilution and sub-
sequent dialysis against serum-free cell-culture medium. Resulting
equimolar concentrations were double-checked to spot dialysis-
associated protein loss.Dose-dependent induction of IL-6 release primarily by full-length
matrilin-3 and the oligomeric A1cc domain
To investigate which matrilin-3 domain(s) is/are responsible for
induction of IL-6, we incubated PHCs with full-lengthmatrilin-3 and
the different truncated matrilin-3 proteins in various equimolar
concentrations (Fig. 3) calculated on the basis of the molecular
weights given in Fig. 1. Incubationwith full-lengthmatrilin-3 yieldedin the case of dCT) different donors were stimulated with matrilin-3 (ﬂc) or matrilin-3
ere harvested and IL-6 levels determined by ELISA. All results are presented as relative
atrilin-3, the monomeric dCT as well as the oligomeric A1cc and 4EGF domains induce
ates signiﬁcant/highly signiﬁcant results (i.e., differences between induced and control
ance of dose dependency if different from the statistical signiﬁcance of differences.
Fig. 5. Depletion of matrilin-3 and the dCT and A1cc domains from culture medium.
PHCs from four (matrilin-3), twelve (dCT) or six (A1cc) donors were incubated with
200 nM matrilin-3 (ﬂc), the dCT or A1cc domain in culture medium, or matrilin-3-
depleted (pulldown, pd) culture medium. Subsequently, cell supernatants were har-
vested and IL-6 levels determined by ELISA. Depletion of matrilin-3 or the dCT and
A1cc domains led to reduced IL-6 release, indicating the speciﬁcity of the induction of
IL-6 by matrilin-3 proteins. Results are presented as relative release, i.e., release
relative to basal release in control cultures. Error bars represent the 95% conﬁdence
interval. **/# indicates highly/nearly signiﬁcant differences.
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n¼ 6e dosedependency: P¼ 0.001, r¼ 0.615,n¼ 6). Incubationwith
the monomeric dCT domain, consisting of the VWA and the four EGF
domains, also led to a highly signiﬁcant dose-dependent release of
IL-6 (P ¼ 6.1  107, F ¼ 15.234, n ¼ 12 e dose dependency:
P¼1.0108, r¼0.713,n¼12), but compared to full-lengthmatrilin-
3, the induction bydCTwas less pronounced. Incubation of PHCswith
the monomeric A1 (P ¼ 0.582, F ¼ 0.668, n ¼ 6 e dose dependency:
P ¼ 0.259, r ¼ 0.240, n ¼ 6) and monomeric 4EGF (P ¼ 0.959,
F¼0.100,n¼6edosedependency:P¼0.911, r¼0.024,n¼6)domain
did not result in IL-6 release, whereas the oligomeric A1cc domain
caused a strong and highly signiﬁcant release of IL-6 (P¼ 8.8 104,
F¼ 10.665, n¼ 7e dose dependency: P¼ 2.6104, r¼ 0.717, n¼ 7).
The oligomeric 4EGFcc domain only gave a very weak, yet highly
signiﬁcant release of IL-6 (P ¼ 6.5  106, F ¼ 29.349, n ¼ 6 e dose
dependency: P ¼ 1.8  106, r ¼ 0.876, n ¼ 6) (Fig. 3).
The limited yield of primary cells, as well as the use of different
concentrations and controls, made it impractical to carry out parallel
investigations of PHCs from the same donor comprising the whole
protein and concentration scale. Therefore, as an alternative, we
compared the magnitude of the IL-6 gene induction by investigating
the effect of matrilin-3 and matrilin-3 domains in parallel with PHCs
from eight different donors at one deﬁned concentration (Fig. 4).
Incubation of PHCswith the A1cc domain gave the strongest effect on
IL-6 release, followed by full-length matrilin-3. In comparison, the
dCT and the 4EGFcc domains led to a moderate IL-6 release, while
the othermatrilin-3 proteins hadminimal effects on IL-6 release. The
effect on IL-6 release was signiﬁcant for monomeric A1 (P ¼ 0.022,
F ¼ 6.644, n ¼ 8) and highly signiﬁcant for the remainder of the
proteins (dCTdomain (P¼ 6.7104, F¼ 18.898,n¼ 8), A1cc domain
(P ¼ 0.009, F ¼ 9.333, n ¼ 8), full-length matrilin-3 (P ¼ 1.3  104,
F ¼ 27.051, n ¼ 8), 4EGFcc domains (P ¼ 0.001, F ¼ 16.921, n ¼ 8),
monomeric 4EGF (P ¼ 8.9  104, F ¼ 17.625, n ¼ 8)).
To verify that IL-6 release is speciﬁcally induced by matrilin-3,
PHCs were incubated in culture medium depleted of matrilin-3
proteins by incubation with Strep-Tactin Superﬂow resin prior to
stimulation. Depletion caused a highly signiﬁcant reduction of IL-6
release for full-length matrilin-3 (P ¼ 0.001, F ¼ 33.107, n ¼ 4) and
the dCT domain (P ¼ 9.4  104, F ¼ 14.559, n ¼ 12), and a nearly
signiﬁcant reduction of IL-6 for the A1cc domains (P ¼ 0.088,
F ¼ 3,562, n ¼ 6) (Fig. 5).Fig. 4. Magnitude of IL-6 gene induction by matrilin-3 proteins. PHCs from eight
different donors were incubated with 200 nM matrilin-3 proteins. Cell-culture su-
pernatants were harvested and IL-6 levels determined by ELISA. All results are pre-
sented as relative release, i.e., release relative to basal release in control cultures. Error
bars represent the 95% conﬁdence interval. */** indicates signiﬁcant/highly signiﬁcant
results (i.e., differences between induced and control values). # indicates nearly
signiﬁcant results.Discussion
Our results show that the VWA1 domain of matrilin-3 is
responsible for release of IL-6 and, furthermore, that it must be
present in an oligomeric form to strongly stimulate IL-6 release. To
this day, a receptor for matrilin-3 VWA1 domain-mediated release
of IL-6 has not been identiﬁed. Earlier studies have shown that
integrins weakly interact with matrilins, but the binding does not
lead to formation of focal contacts and reorganization of the actin
cytoskeleton7. In addition, cell-surface proteoglycans have been
implicated in the weak promotion of cell attachment viamatrilins7.
Integrin activity and the cell adhesion-signaling phenotype can be
regulated by clustering of the integrin receptors as well as by co-
receptor interactions with cell-surface proteoglycans8. Consid-
ering the lack of signal transduction by the monomeric VWA1
domain, it is possible that the oligomeric structure of matrilin-3
provides clustering of integrins and/or cell-surface proteoglycans
or the activation of a still unknown receptor due to the high avidity
provided by the multivalency of the matrilin oligomers.
The matrilin-3 dCT protein consists of a VWA1 and 4EGF
domain. In contrast to the isolated VWA1 and 4EGF domains, in-
cubation of PHCs with the dCT domain led to a moderate release of
IL-6. However, it is uncertain why the monomeric VWA1 domain
did not cause IL-6 release, while the monomeric dCT domain did. It
is possible that the EGF domains binds to an as yet unidentiﬁed
receptor and thus acts as a co-receptor ligand. This hypothesis is
supported by the recent ﬁnding that matrilin-3 can bind to the
a5b1 integrin, leading to cell adhesion and Protein kinase B (AKT)
activation in an EGF1-dependent manner9. So far, it has been
assumed that the VWA domains are the principal interaction do-
mains of matrilins and that the EGF domains serve as spacers. This
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that splice variants lacking EGF domains are found in zebraﬁsh10. In
the light of our new results as well as the a5b1 integrin addressed
above we put forward the hypothesis that both the VWA1 and the
EGF domains are functional in modulating the gene expression
proﬁle of PHCs and thus cartilage homeostasis. Further studies will
be aimed at showing which genes are activated by the VWA1 and
the 4EGF domain or if they act in concert on the same genes.
The PHCs used in our study originate from osteoarthritic human
knee joints and represent a mixture of chondrocytes from
Osteoarthritis (OA)-affected and unaffected regions. The two kinds
of chondrocytes probably differ in their response to matrilin-3
stimulation, a difference that was not analyzed in our experi-
ments and the implications of which have been discussed
elsewhere1.
Over the past few years, it has become obvious that the Extra-
cellular matrix (ECM) is more than just a rigid network for cell
attachment. Many studies show that matrix proteins can inﬂuence
gene expression and regulate cartilage homeostasis in addition to
their function as structural components and adapters, thus playing
an important role for cartilage maintenance in health and cartilage
degradation in disease. As a result of its modular composition,
matrilin-3 is an important tissue-speciﬁc regulator of cartilage
homeostasis. This impact on cartilage homeostasis is regulated at
the level of gene expression, by alternative splicing, oligomeriza-
tion, matrix integration, and proteolytic processing 1,2,9.
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